Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Sopheon PLC Issue of Equity 02/10/2017 7:00am UK Regulatory (RNS & others) Sopheon (LSE:SPE) Intraday Stock Chart Today : Monday 2 October 2017 Click Here for more Sopheon Charts. TIDMSPE RNS Number : 3154S Sopheon PLC 02 October 2017 For immediate release SOPHEON PLC ("Sopheon" or the "Company") Issue of Equity Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Management, announces today that it has issued and allotted 10,000 ordinary shares of 20 pence each in the capital of the Company ("Ordinary Shares") in connection with the exercise of share options. Application has been made for the 10,000 new Ordinary Shares to be admitted to trading on AIM, and dealings are expected to commence on 3 October 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 7,463,431. The Company does not hold any shares in treasury. Accordingly, the figure of 7,463,431 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. Mvg Trinko
Toch vandaag 38k omzet met gelijkblijvende koers. Gr Arie de Beuker
Ja is niet veel qua omzet of wat?
Heb je helemaal gelijk in Harry, fijn weekend
zo is dat gart,mensen die geen soof aandelen hebben,kan je maar beter gelijk geven, tijd voor een pilsie:)
Vraag niet hoe het kan ..., maar als iemand een oorzaak heeft, mooi 7%.
Dan ook gewoon niet vragen:-)))
Oorzaak is simpelweg dat men graag aandeeltjes wil en denkt dat dat op korte termijn niet goedkoper kan. Waarom anders instappen op deze prijs? Ik zit al een tijd te wachten op een doorbraak, inmiddels gaan de ontwikkelingen bij Sopheon gewoon door. Alleen maar positief nieuws. Het bedrijf is nu grofweg 30 miljoen pond waard. Eens kijken of de koers nu wel doorzet..... Klaas
De directie heeft zelf wel vertrouwen:-)) Sopheon PLC Director/PDMR Shareholding 11/10/2017 10:44am UK Regulatory (RNS & others) Sopheon (LSE:SPE) Intraday Stock Chart Today : Wednesday 11 October 2017 Click Here for more Sopheon Charts. TIDMSPE RNS Number : 3174T Sopheon PLC 11 October 2017 For Immediate Release SOPHEON PLC ("Sopheon" or the "Company") DIRECTOR SHAREHOLDINGS Sopheon has been notified that certain directors of the Company have purchased shares in the Company. Barry Mence has purchased 3,000 ordinary shares of 20 pence each in the capital of the Company ("Ordinary Shares") in his Individual Savings Account ("ISA"). Barry Mence's spouse Maria Mence has purchased 2,750 Ordinary Shares in her ISA. The above shares were purchased at a price of GBP3.97 each. In addition, Barry Mence has transferred 2,000 Ordinary Shares from being held in his Self Invested Personal Pension ("SIPP") to his ISA, and he has also transferred 3,000 Ordinary Shares from being held in his SIPP to the ISA of Maria Mence. Barry Mence's total beneficial interest in Ordinary Shares, including those held by his wife, has accordingly increased by 5,750 Ordinary Shares to 1,458,326 Ordinary Shares. Stuart Silcock has purchased 625 Ordinary Shares in his dealing account. Stuart Silcock's spouse Christine Silcock has purchased 1,250 Ordinary Shares in her dealing account and a further 625 Ordinary Shares in her ISA. The above shares were purchased at a price of GBP3.97 each. In addition, Stuart Silcock has transferred 7,000 Ordinary Shares from being held in his SIPP to his ISA. Stuart Silcock's total beneficial interest in Ordinary Shares, including those of his wife, as well as his interest in Ordinary Shares held in Bare Trust for his grandchildren has accordingly increased by 2,500 Ordinary Shares to 279,627 Ordinary Shares. Trinko
mogge, dit is de 3de keer dat ze deze aantallen kopen,bestuurders + famillie, lijkt niet veel,maar dat 3keer doen ,kom je toch aan flinke aantallen,ze gaan echt niet kopen,als ze weten dat de nabije toekomst er slecht uit gaat zien, de voorzitter en zn bestuurders weten, natuurlijk veel meer dan ons, wat er allemaal nog komen gaat.
ik zeg wel mogge,het is middag onderhand.
Ik weet bijna zeker dat ze dividend gaan uitkeren. Let maar op. Het gaat gewoon goed met Sopheon anders kopen ze echt niet voor hun oude dag. Gr Arie de Beuker
Dividend mogen ze in hun bolle r..t stoppen, laten ze maar zorgen voor een overname prijs van 8 tot 10 euro;-))))
mogge,ja een overname ben ik ook voor, goed bod en het boek soof sluiten, we kunnen wel wachten tot sint juttemus,maar we worden ook een dagje ouder he, en die dividend zit ik ook niet op te wachten.
Hallootjes... Zit niet echt vaart in he..lage volumes..jojo een beetje rond de 4 euro.. Wordt het nog wat denkt iemand?
Sopheon Awarded Funding for European Research Projects Funding recognizes Sopheon’s ongoing contribution to research on market disruptors such as Internet of Things, real-time decision support, and advanced analytics embedded into business process Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution and PARTNER. Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon’s contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners - research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors – to develop breakthrough capabilities for commercial application in our software. In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources – structured and unstructured data; metadata from sensor data, images, video – and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc. The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system. Huub Rutten, VP Research and Application Development at Sopheon, stated: “For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application.” This award brings to a total of five the number of research grants awarded to Sopheon since 2009. Sopheon® and Accolade® are trademarks of Sopheonwww.sopheon.com/sopheon-awarded-fundi... Bertus S.
Dat is een mooie erkenning wederom. Ze blijven zich erg goed ontwikkelen. Healthcare is een grote markt, Sopheon's exposure daarin wordt alsmaar groter. Dat moet zijn vruchten gaan afwerpen, dat kan niet anders. Klaas
het soof gebouw moet onderhand,helemaal propvol zitten met gewonnen prijzen,nu de koers nog.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Indices
AEX
871,16
-0,33%
EUR/USD
1,0698
+0,00%
FTSE 100
8.073,17
+0,41%
Germany40^
17.889,50
-1,10%
Gold spot
2.330,13
+0,61%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers